Silexion Secures $1M Lifeline in High-Stakes Cancer Drug Race

GRAND CAYMAN – May 15, 2026 – Silexion Therapeutics (NASDAQ: SLXN), a clinical-stage biotechnology company, announced today it has secured approximately $1 million in gross proceeds through a complex financing deal. The move provides a much-needed, albeit modest, cash infusion as the company pushes its novel cancer therapy toward critical human trials, but it comes at a significant cost to existing shareholders.

The transaction involves the immediate exercise of nearly two million outstanding warrants at a reduced price of $0.50 per share. To incentivize this, Silexion is issuing a substantial number of new warrants, a financial maneuver that underscores the intense pressure on small biotech firms to fund groundbreaking research in a challenging market.

A High-Stakes Financial Maneuver

In a deal structured by exclusive placement agent H.C. Wainwright & Co., holders of warrants originally issued in 2025 agreed to exercise them for cash. In return, Silexion will issue new unregistered Series C and Series D warrants to purchase an additional four million ordinary shares, also at an exercise price of $0.50 per share.

This type of arrangement, often called a "warrant inducement," is a tool used by companies with depressed stock prices to accelerate capital inflow. With Silexion's stock trading at $0.50—down 96% over the past year and hovering near its 52-week low—conventional financing routes can be difficult and expensive. This deal provides immediate working capital, which the company states will be used for general corporate purposes, effectively fueling its operations as it advances its clinical programs.

While the gross proceeds are stated at $1 million, the net amount available to Silexion will be lower after deducting placement agent fees and other offering expenses. For a company with a reported negative earnings per share of -3.87 and a high cash burn rate typical of its sector, every dollar is critical. However, the structure of the deal itself speaks volumes about the financial tightrope the company is walking.

The Specter of Dilution

The immediate benefit of cash comes with a heavy long-term consequence: significant shareholder dilution. Silexion had approximately 4.1 million ordinary shares outstanding as of early May. The immediate exercise of warrants adds nearly 2 million shares to that total.

More consequentially, the issuance of new Series C and D warrants introduces the potential for another 4 million shares to enter the market, subject to shareholder approval. If all new warrants are eventually exercised, the company’s share count could more than double, drastically reducing the ownership stake of current investors.

This potential dilution is a stark reality for investors in the high-risk, high-reward world of clinical-stage biotech. The decision to accept such terms reflects a trade-off between securing the necessary funds to continue potentially life-saving research and preserving shareholder value. For Silexion, with its market capitalization languishing around $2 million, the choice was likely one of necessity to keep its ambitious scientific goals on track.

Fueling the Fight Against an "Undruggable" Foe

The capital, while dilutive, is aimed at one of the most formidable targets in oncology: cancers driven by mutations in the KRAS gene. Found in roughly 30% of all human tumors, KRAS mutations are particularly prevalent in some of the deadliest cancers, including pancreatic ductal adenocarcinoma (~90%), colorectal cancer (~45%), and non-small cell lung cancer (~30%).

For decades, KRAS was considered "undruggable" due to its protein structure. While recent breakthroughs from giants like Amgen and Bristol Myers Squibb have led to approved small-molecule inhibitors targeting a specific mutation, KRAS G12C, the field remains intensely competitive and filled with unmet needs.

This is where Silexion aims to differentiate itself. The company’s lead candidate, SIL204, is not a small molecule inhibitor. Instead, it is a small interfering RNA (siRNA) therapy. This RNA interference (RNAi) technology works by a fundamentally different mechanism: it aims to silence the mutated KRAS gene itself, preventing the cell from producing the cancer-driving protein in the first place. Silexion believes this approach may overcome some of the resistance mechanisms seen with protein inhibitors and could be effective against a wider array of KRAS mutations beyond G12C, including G12D, G12V, and others common in pancreatic cancer.

From Lab to Clinic: A Race Against Time

Silexion is not just selling a scientific theory; it is making tangible progress toward clinical validation. The company is advancing SIL204 towards a pivotal Phase 2/3 clinical trial for locally advanced pancreatic cancer, a disease with a grim prognosis.

Key regulatory and operational milestones have recently been achieved. Silexion has already secured approval from the Israeli Ministry of Health to initiate the trial and has received ethics committee approval at a major medical center in Tel Aviv. Critically, the company also submitted its Clinical Trial Application in Germany, which will act as the lead country for scientific assessment across the European Union.

With trial initiation planned for the second quarter of 2026 across Israel and the EU, the company has also commenced Good Manufacturing Practice (GMP) production of SIL204 with its partner Catalent. This step is essential for producing the clinical-grade material required for human trials and signals a serious commitment to moving forward. The planned trial will test an innovative dual-route administration, combining direct tumor injection with systemic infusion to fight both primary tumors and metastatic spread.

This progress provides the crucial context for the recent financing. The funds are not for an abstract idea but for executing a concrete clinical plan. For Silexion, its investors, and the patients it hopes to treat, the race is on to prove that its unique RNAi platform can translate from promising preclinical data into a meaningful therapy against one of cancer's most challenging targets.